• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统分析白细胞介素 6(IL-6)作为非小细胞肺癌患者免疫治疗反应的预测生物标志物和脱敏剂。

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer.

机构信息

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

出版信息

BMC Med. 2022 May 13;20(1):187. doi: 10.1186/s12916-022-02356-7.

DOI:10.1186/s12916-022-02356-7
PMID:35550592
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9102328/
Abstract

BACKGROUND

Cytokines have been reported to alter the response to immune checkpoint inhibitors (ICIs) in patients with the tumor in accordance with their plasma concentrations. Here, we aimed to identify the key cytokines which influenced the responses and stimulated resistance to ICIs and tried to improve immunological response and develop novel clinical treatments in non-small cell lung cancer (NSCLC).

METHODS

The promising predictive cytokines were analyzed via the multi-analyte flow assay. Next, we explored the correlation baseline level of plasma cytokines and clinical outcomes in 45 NSCLC patients treated with ICIs. The mechanism of the potential candidate cytokine in predicting response and inducing resistance to ICIs was then investigated.

RESULTS

We found NSCLC with a low baseline concentration of IL-6 in plasma specimens or tumor tissues could derive more benefit from ICIs based on the patient cohort. Further analyses revealed that a favorable relationship between PD-L1 and IL-6 expression was seen in NSCLC specimens. Results in vitro showed that PD-L1 expression in the tumor was enhanced by IL-6 via the JAK1/Stat3 pathway, which induced immune evasion. Notably, an adverse correlation was found between IL-6 levels and CD8 T cells. And a positive association between IL-6 levels and myeloid-derived suppressor cells, M2 macrophages and regulator T cells was also seen in tumor samples, which may result in an inferior response to ICIs. Results of murine models of NSCLC suggested that the dual blockade of IL-6 and PD-L1 attenuated tumor growth. Further analyses detected that the inhibitor of IL-6 stimulated the infiltration of CD8 T cells and yielded the inflammatory phenotype.

CONCLUSIONS

This study elucidated the role of baseline IL-6 levels in predicting the responses and promoting resistance to immunotherapy in patients with NSCLC. Our results indicated that the treatment targeting IL-6 may be beneficial for ICIs in NSCLC.

摘要

背景

据报道,细胞因子会根据其在血浆中的浓度改变肿瘤患者对免疫检查点抑制剂(ICI)的反应。在这里,我们旨在确定影响反应并刺激对 ICI 产生耐药性的关键细胞因子,并试图改善免疫反应并为非小细胞肺癌(NSCLC)开发新的临床治疗方法。

方法

通过多分析物流式细胞术分析有前途的预测细胞因子。接下来,我们探索了 45 名接受 ICI 治疗的 NSCLC 患者的基线血浆细胞因子水平与临床结局之间的相关性。然后研究了潜在候选细胞因子在预测 ICI 反应和诱导耐药性中的作用机制。

结果

我们发现,根据患者队列,基线血浆标本或肿瘤组织中 IL-6 浓度较低的 NSCLC 患者可能从 ICI 中获益更多。进一步分析显示,在 NSCLC 标本中观察到 PD-L1 表达与 IL-6 表达之间存在良好的关系。体外结果表明,IL-6 通过 JAK1/Stat3 通路增强肿瘤中的 PD-L1 表达,从而诱导免疫逃逸。值得注意的是,IL-6 水平与 CD8 T 细胞之间存在负相关。在肿瘤样本中还观察到 IL-6 水平与髓源性抑制细胞、M2 巨噬细胞和调节性 T 细胞之间存在正相关,这可能导致对 ICI 的反应较差。NSCLC 小鼠模型的结果表明,IL-6 和 PD-L1 的双重阻断减弱了肿瘤生长。进一步分析检测到,IL-6 抑制剂刺激了 CD8 T 细胞的浸润,并产生了炎症表型。

结论

本研究阐明了基线 IL-6 水平在预测 NSCLC 患者对免疫治疗的反应和促进耐药性中的作用。我们的结果表明,针对 IL-6 的治疗可能对 NSCLC 的 ICI 有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/43b366bc884f/12916_2022_2356_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/35c66349e45e/12916_2022_2356_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/d046461a9fca/12916_2022_2356_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/840d7b83a003/12916_2022_2356_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/a065a213b52e/12916_2022_2356_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/43b366bc884f/12916_2022_2356_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/35c66349e45e/12916_2022_2356_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/d046461a9fca/12916_2022_2356_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/840d7b83a003/12916_2022_2356_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/a065a213b52e/12916_2022_2356_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ea2/9102328/43b366bc884f/12916_2022_2356_Fig5_HTML.jpg

相似文献

1
Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer.系统分析白细胞介素 6(IL-6)作为非小细胞肺癌患者免疫治疗反应的预测生物标志物和脱敏剂。
BMC Med. 2022 May 13;20(1):187. doi: 10.1186/s12916-022-02356-7.
2
KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.KRAS-G12D 突变驱动免疫抑制和抗 PD-1/PD-L1 免疫疗法在非小细胞肺癌中的原发性耐药。
Cancer Commun (Lond). 2022 Sep;42(9):828-847. doi: 10.1002/cac2.12327. Epub 2022 Jul 11.
3
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.ILT4 抑制可预防 TAM 和功能失调 T 细胞介导的免疫抑制,并增强 EGFR 激活的 NSCLC 中抗 PD-L1 治疗的疗效。
Theranostics. 2021 Jan 19;11(7):3392-3416. doi: 10.7150/thno.52435. eCollection 2021.
4
Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.全面综述:揭示 IL-1ß 和 PD-1/PD-L1 在 NSCLC 发展中的致癌作用,并针对其通路进行临床管理。
Int J Mol Sci. 2023 Jul 17;24(14):11547. doi: 10.3390/ijms241411547.
5
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用:现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
6
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性:一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
7
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.抗 PD-1/PD-L1 免疫疗法疗效的分子异质性与东亚非小细胞肺癌患者的肿瘤免疫微环境相关。
Cancer Biol Med. 2020 Aug 15;17(3):768-781. doi: 10.20892/j.issn.2095-3941.2020.0121.
8
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.基质 PD-L1 阳性调节性 T 细胞和 PD-1 阳性 CD8 阳性 T 细胞定义了不同亚组非小细胞肺癌对 PD-1/PD-L1 阻断免疫治疗的反应。
J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.
9
Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.基线细胞外囊泡转化生长因子-β是预测非小细胞肺癌对免疫检查点抑制剂反应及生存情况的生物标志物。
Cancer. 2023 Feb 15;129(4):521-530. doi: 10.1002/cncr.34576. Epub 2022 Dec 9.
10
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.生命之光:免疫评分免疫检查点,免疫治疗反应的预测指标。
Oncoimmunology. 2023 Aug 5;12(1):2243169. doi: 10.1080/2162402X.2023.2243169. eCollection 2023.

引用本文的文献

1
RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations.RANKL/PD-1双重阻断对携带KRAS突变的晚期肺腺癌患者显示出生存获益。
Cell Rep Med. 2025 Jul 15;6(7):102235. doi: 10.1016/j.xcrm.2025.102235.
2
Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study.利用血浆蛋白质组学进行液体活检以预测非小细胞肺癌中PD-1/PD-L1阻断疗法的疗效和耐受性:一项前瞻性探索性研究。
Mol Biomed. 2025 Jul 15;6(1):51. doi: 10.1186/s43556-025-00291-6.
3
Point of care sepsis diagnosis: Exploring microfluidic techniques for sample preparation, biomarker isolation, and detection.

本文引用的文献

1
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.白细胞介素 6 阻断剂在癌症免疫治疗中预防和管理免疫相关不良事件的应用。
Eur J Cancer. 2021 Nov;157:214-224. doi: 10.1016/j.ejca.2021.08.031. Epub 2021 Sep 15.
2
The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors.细胞因子在预测免疫检查点抑制剂相关反应和不良事件中的作用
Front Immunol. 2021 Jul 22;12:670391. doi: 10.3389/fimmu.2021.670391. eCollection 2021.
3
Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
床旁脓毒症诊断:探索用于样品制备、生物标志物分离和检测的微流控技术。
Biomicrofluidics. 2025 Jul 1;19(4):041502. doi: 10.1063/5.0248096. eCollection 2025 Jul.
4
Interleukin-7 enhances recruitment of MDSCs by regulating MCP-1 via JAK1/STAT3 signaling pathway in non-small cell lung cancer.白细胞介素-7通过JAK1/STAT3信号通路调控单核细胞趋化蛋白-1,从而增强非小细胞肺癌中髓源性抑制细胞的募集。
Sci Rep. 2025 May 15;15(1):16869. doi: 10.1038/s41598-025-01868-5.
5
Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion.胸膜内双重阻断白细胞介素-6和程序性死亡配体1可重塑肺癌相关恶性胸腔积液中癌症相关成纤维细胞的动态变化及肿瘤微环境。
Respir Res. 2025 May 10;26(1):180. doi: 10.1186/s12931-025-03263-0.
6
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy.在接受免疫疗法、化疗或化疗免疫疗法治疗的OXEL试验中,三阴性乳腺癌患者的血清分析物作为疾病复发和无侵袭性疾病生存期的预测指标。
J Immunother Cancer. 2025 Apr 23;13(4):e011379. doi: 10.1136/jitc-2024-011379.
7
Mechanistic insight for T-cell exclusion by cancer-associated fibroblasts in human lung cancer.人肺癌中癌症相关成纤维细胞导致T细胞排斥的机制洞察
Elife. 2025 Apr 10;13:RP101885. doi: 10.7554/eLife.101885.
8
Combining interleukin 6 and EBV DNA levels predicts survival outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving chemoimmunotherapy.联合白细胞介素6和EBV DNA水平可预测接受化学免疫治疗的复发或转移性鼻咽癌患者的生存结局。
Front Immunol. 2025 Mar 14;16:1560897. doi: 10.3389/fimmu.2025.1560897. eCollection 2025.
9
Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer.在PD-L1高表达的肺癌中,细胞内源性PD-L1信号通过IL-6/Jak/Stat3途径驱动髓源性抑制细胞产生免疫抑制作用。
J Immunother Cancer. 2025 Mar 6;13(3):e010612. doi: 10.1136/jitc-2024-010612.
10
Predictive value of serum cytokines in patients with non-small-cell lung cancer receiving anti-PD-1 blockade therapy: a meta-analysis.血清细胞因子对接受抗程序性死亡蛋白1阻断治疗的非小细胞肺癌患者的预测价值:一项荟萃分析。
Clin Exp Med. 2025 Feb 16;25(1):59. doi: 10.1007/s10238-025-01587-1.
融合 Rab37/IL-6 转运和 STAT3/PD-1 转录轴引发免疫抑制性肺肿瘤微环境。
Theranostics. 2021 May 12;11(14):7029-7044. doi: 10.7150/thno.60040. eCollection 2021.
4
Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma.东亚肺腺癌患者中与表皮生长因子受体(EGFR)突变相关的综合免疫临床预后模型的建立与外部验证
Ther Adv Med Oncol. 2021 Apr 8;13:17588359211006949. doi: 10.1177/17588359211006949. eCollection 2021.
5
Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.重新审视经典霍奇金淋巴瘤肿瘤微环境中的 IL-6 表达。
Blood Adv. 2021 Mar 23;5(6):1671-1681. doi: 10.1182/bloodadvances.2020003664.
6
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC.非小细胞肺癌患者的血浆 IL-6 变化与 PD-1 抑制剂反应相关。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-000678.
7
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors.基线血清白细胞介素-6水平可预测晚期非小细胞肺癌患者对PD-1/PD-L1抑制剂的反应。
Immune Netw. 2020 May 20;20(3):e27. doi: 10.4110/in.2020.20.e27. eCollection 2020 Jun.
8
Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.免疫检查点抑制剂转换为 MEK/ BRAF 抑制剂后出现细胞因子释放综合征患者应用 IL-6 阻滞剂成功治疗:病例报告及文献复习。
Oncologist. 2020 Jul;25(7):e1120-e1123. doi: 10.1634/theoncologist.2020-0194. Epub 2020 Jun 2.
9
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.肺腺癌患者 PD-L1 表达的临床和分子相关性。
Ann Oncol. 2020 May;31(5):599-608. doi: 10.1016/j.annonc.2020.01.065. Epub 2020 Feb 6.
10
The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs).白细胞介素 6 在免疫相关不良反应(irAEs)的非小细胞肺癌(NSCLC)免疫治疗中的作用。
Thorac Cancer. 2020 Apr;11(4):835-839. doi: 10.1111/1759-7714.13341. Epub 2020 Feb 11.